For the first two years, the antidepressant medication worked. Rachel could feel it working. The sertraline her psychiatrist prescribed after her second depressive episode had lifted the gray weight from her mornings, restored her appetite, and made it possible to return to teaching her fourth-grade class in San Luis Obispo with something resembling her former energy. She’d told friends the medication saved her life. She meant it.
Then, somewhere around month twenty-six, she noticed the fog rolling back in. Not all at once—it was subtle enough that she dismissed it at first. A little more tired than usual. A little harder to get out of bed. A growing reluctance to return phone calls. She assumed it was stress. End-of-school-year exhaustion. The Central Coast’s unusually overcast spring.
But by summer, when the sky was clear and the days were long and she should have been enjoying the break, Rachel knew something had changed. The medication that had given her back her life had, quietly and without warning, stopped working. Her depression was back. And this time, it came with an additional weight: the crushing fear that she had run out of options.
If you’ve experienced something like this, you’re far from alone. And despite what it feels like in that moment, you are not out of options.
What’s Actually Happening When Medication Stops Working
The experience Rachel described has a clinical name: antidepressant tachyphylaxis. Often referred to colloquially as “antidepressant poop-out” or “breakthrough depression,” it describes a specific phenomenon in which a patient who initially responded well to an antidepressant medication experiences a return or worsening of depressive symptoms despite remaining on the same drug at the same dose.
This isn’t the same as the medication never working in the first place. And it isn’t the same as a new depressive episode caused by external stressors. Tachyphylaxis occurs when the brain gradually adapts to the presence of the medication, diminishing its therapeutic effect through a process related to neuroadaptation and receptor desensitization.
The prevalence of antidepressant tachyphylaxis is more common than most patients—and even some providers—realize. Research indicates that between 9% and 57% of patients who initially respond to antidepressant medication will experience a loss of efficacy during continued treatment, depending on the population studied and the duration of follow-up (Kinney & Taber, 2019). A landmark study found that 33.7% of patients who achieved full remission on fluoxetine experienced symptom recurrence within 14 to 54 weeks despite staying on the same dose (Fava et al., 1995, as cited in Rothschild, 2008).
These numbers tell an important story: if your medication has stopped working, you are not an outlier. This is a recognized, well-documented phenomenon that affects a significant proportion of people taking antidepressants.
Why Antidepressants Lose Their Effectiveness
Understanding why this happens requires a look at how these medications work—and what they don’t address.
Receptor desensitization. Most commonly prescribed antidepressants—SSRIs and SNRIs—work by blocking the reuptake of serotonin (and, in the case of SNRIs, norepinephrine), making these neurotransmitters more available in the synaptic space between neurons. Initially, this increased availability produces the desired effect: improved mood, better sleep, reduced anxiety. But over time, the brain’s receptors can become less sensitive to the elevated neurotransmitter levels, essentially recalibrating to the new baseline. The result is that the same dose produces less effect—not because the drug has changed, but because the brain has adapted to it.
The serotonin limitation. While the serotonin hypothesis has dominated depression treatment for decades, we now understand that depression involves far more than serotonin deficiency. The glutamate system—the brain’s most abundant neurotransmitter network—plays a critical role in mood regulation, cognitive flexibility, and neuroplasticity. Standard antidepressants don’t directly address glutamate dysfunction, which may explain why they fail to produce lasting relief for a significant subset of patients.
Neuroplasticity decline. Chronic depression is associated with reduced levels of Brain-Derived Neurotrophic Factor (BDNF), a protein essential for the growth, survival, and adaptability of neurons. When BDNF is depleted, the brain’s capacity to form new connections and break out of entrenched depressive patterns diminishes. Some researchers have suggested that long-term antidepressant use may, in certain cases, paradoxically contribute to neuroplasticity decline, potentially making the brain more vulnerable to relapse over time.
Underlying condition progression. Depression is not always a static condition. For some individuals, the underlying illness may progress or evolve over time, outpacing the medication’s ability to manage it. Additionally, emerging research suggests that repeated depressive episodes may make the brain more susceptible to future episodes, a concept known as “kindling”—which underscores the importance of effective early treatment.
The Emotional Weight of Treatment Failure
The clinical aspects of antidepressant tachyphylaxis are challenging enough. But the emotional toll deserves equal attention, because it profoundly affects what happens next.
When a medication stops working, patients don’t just lose symptom relief. They often lose hope. The internal narrative shifts from “I’m managing my depression” to “My depression is unmanageable.” The experience of having something work and then failing can feel more devastating than never having found relief at all—because now you know what you’re missing.
There’s also a pervasive misconception that treatment-resistant depression reflects something wrong with the patient rather than a limitation of the treatment. This misconception keeps people stuck, ashamed, and reluctant to explore alternative approaches. It’s worth stating clearly: if your antidepressant has stopped working, it is not your fault. Your brain’s response to a medication is a neurobiological event, not a moral failing.
Many patients who come to Innerbloom Ketamine Therapy describe years of cycling through medications—adding, switching, augmenting—before learning that options beyond the serotonin-based model exist. The exhaustion of that process is real, and we honor it.
Understanding Treatment-Resistant Depression
Treatment-resistant depression (TRD) is generally defined as depression that has not responded adequately to at least two different antidepressant medications taken at appropriate doses for an adequate duration. By some estimates, roughly one-third of the nearly nine million Americans treated for depression each year meet criteria for TRD.
It’s important to understand that “treatment-resistant” doesn’t mean “untreatable.” It means that the specific treatments tried so far haven’t been effective. The distinction matters, because the label can feel like a life sentence when it’s actually a signpost pointing toward different approaches.
When antidepressants stop working, standard clinical responses typically include dose adjustment (increasing the current medication), medication switching (trying a different drug, often from a different class), augmentation strategies (adding a second medication such as an atypical antipsychotic, lithium, or thyroid hormone), and combination therapy (pairing two antidepressants with different mechanisms).
These strategies help some patients, and they remain valuable tools. But for those who have already cycled through multiple medications without sustained relief, they represent more of the same fundamental approach: adjusting neurotransmitter levels through the same receptor systems. For patients whose depression involves glutamate dysfunction, diminished neuroplasticity, or other mechanisms beyond the serotonin model, a fundamentally different treatment pathway may be needed.
Ketamine: A Different Mechanism for a Different Problem
This is where ketamine therapy enters the conversation—not as a replacement for everything that came before, but as a treatment that works through an entirely different mechanism.
While SSRIs and SNRIs target the serotonin and norepinephrine systems, ketamine acts primarily on the glutamate system by modulating NMDA receptors. This triggers a cascade of neurobiological events that address several of the specific deficits associated with treatment-resistant depression. Ketamine rapidly increases BDNF levels, promoting the growth and strengthening of synaptic connections that chronic depression has weakened. It enhances neuroplasticity, allowing the brain to form new pathways and break free from the rigid patterns that keep depressive symptoms entrenched. It provides rapid symptom relief—often within hours rather than weeks—offering a critical window of clarity for patients who have been suffering without reprieve. And the neuroplastic changes ketamine promotes can make concurrent therapies—psychotherapy, lifestyle interventions, even existing medications—more effective by restoring the brain’s capacity to respond and adapt.
Research consistently supports ketamine’s efficacy in treatment-resistant populations. Response rates as high as 70% have been observed in clinical settings involving patients who had failed multiple prior treatments. A 2023 update by Canada’s Drug Agency (CDA-AMC) confirmed that ketamine could lead to immediate improvement in depressive symptoms and suicidal ideation compared to placebo in adults with TRD, with the longest observed effect from a single dose lasting up to 28 days (CDA-AMC, 2023).
SPRAVATO® (Esketamine): An FDA-Approved Option
For patients with treatment-resistant depression, SPRAVATO® (esketamine) represents another pathway forward. FDA-approved in 2019 for TRD when used in combination with an oral antidepressant—and approved in 2025 as a standalone treatment for adults with TRD—SPRAVATO® is a nasal spray form of esketamine administered under clinical supervision.
SPRAVATO® works through the same glutamate-modulating mechanism as IV ketamine and offers a significant advantage for many patients: insurance coverage. Because it is FDA-approved specifically for treatment-resistant depression, SPRAVATO® is frequently covered by insurance plans, making it a more accessible option for patients who may face financial barriers to IV ketamine.
At Innerbloom, we offer both IV/IM ketamine and SPRAVATO®, and Dr. Rivas works with each patient to determine which approach best fits their clinical needs, treatment history, and financial situation. For many patients whose antidepressants have stopped working, having both options available means we can tailor treatment to their specific circumstances.
What Comes After the Medication Stops Working
Rachel’s story didn’t end with her medication failing. After consulting with her psychiatrist, she explored ketamine therapy at Innerbloom. She was nervous—not about the treatment itself, but about allowing herself to hope again after the disappointment of her medication’s failure.
What she found was that ketamine didn’t just manage her symptoms; it felt fundamentally different from anything she’d tried before. Within hours of her first infusion, the oppressive heaviness she’d been carrying for months began to ease. Over the course of her treatment series, she described a sensation she hadn’t experienced in years: the ability to think about the future without dread.
Rachel still works closely with her psychiatrist on her overall treatment plan. She continues therapy. She maintains her ketamine treatment with periodic booster sessions. Her depression isn’t “cured”—but it’s managed in a way that allows her to live fully, teach with passion, and engage with the people she loves.
Her path won’t look exactly like yours. But her experience illustrates something important: when one door closes, it doesn’t mean you’ve reached the end of the hallway. Treatment-resistant depression is not a dead end. It’s a redirect.
Key Takeaways
- Antidepressant tachyphylaxis affects 9% to 57% of patients who initially respond to medication, making it a common—not rare—experience that doesn’t reflect personal failure.
- Medications lose effectiveness due to neurobiological adaptation, including receptor desensitization, glutamate system dysfunction, and declining neuroplasticity—not because the patient is doing something wrong.
- Treatment-resistant depression means the treatments tried so far haven’t worked, not that depression is untreatable. Alternative approaches with different mechanisms of action exist.
- Ketamine works through the glutamate system, promoting rapid neuroplastic changes that address the specific deficits that serotonin-based medications may not reach, with response rates as high as 70% in treatment-resistant populations.
- SPRAVATO® (esketamine) offers an FDA-approved, often insurance-covered option for patients with treatment-resistant depression, providing another accessible pathway to relief.
About the Author
Dr. Rivas is a ketamine specialist and board-certified acute care and trauma surgeon with over 12 years of experience in ketamine administration. Before founding Innerbloom Ketamine Therapy in 2022, Dr. Rivas served on the frontlines of emergency and trauma medicine in Santa Maria, CA, and Austin, TX. Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Newy: Bridging the Gap Between Ketamine Treatment and Everyday Wellness
A supplement formulated by Dr. Rivas for enhanced brain and mood support. The formula pairs especially well with ketamine therapy by helping extend and enhance the neuroplasticity effects. That said, the ingredients are equally effective on their own, so it’s a supportive option whether or not someone is undergoing ketamine treatment. Learn more about how Newy supports cognitive function detoxification and cellular repair.
References
Kinney, K. L., & Taber, K. (2019). Tachyphylaxis in major depressive disorder: A review of the current state of research. Journal of Affective Disorders, 245, 488–497. https://www.sciencedirect.com/science/article/abs/pii/S0165032718316859
Rothschild, A. J. (2008). Identification and treatment of antidepressant tachyphylaxis. Innovations in Clinical Neuroscience, 5(9), 28–34. https://pmc.ncbi.nlm.nih.gov/articles/PMC4008298/
CDA-AMC. (2023). Ketamine for adults with treatment-resistant depression or posttraumatic stress disorder: A 2023 update. CADTH Health Technology Review. https://www.ncbi.nlm.nih.gov/books/NBK602384/
Corriger, A., & Pickering, G. (2025). Emerging medications for treatment-resistant depression: A review with perspective on mechanisms and challenges. Brain Sciences, 15(2), 161. https://pmc.ncbi.nlm.nih.gov/articles/PMC11853532/
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015). Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychotherapy and Psychosomatics, 84(2), 72–81. https://pubmed.ncbi.nlm.nih.gov/25721705/
Medical Disclaimer
All content on this website, including but not limited to this article, blog posts, testimonials, and FAQs, is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can provide medical advice, diagnosis, or treatment.
The information provided here is for educational and informational purposes only. It is not intended to replace a consultation with a qualified healthcare provider. If you are experiencing symptoms of depression or any mental health condition, please consult with a licensed mental health professional or your primary care physician.
If you are in crisis or experiencing suicidal thoughts, please call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room immediately.
Innerbloom Ketamine Therapy cannot be held responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to our Terms & Conditions for more information.
Has your antidepressant stopped working? Contact Innerbloom Ketamine Therapy at (805) 592-5085 or visit us at 100 Casa Street, Suite D3, San Luis Obispo, CA 93405. We offer complimentary consultations to discuss whether ketamine therapy or SPRAVATO® might be the next step in your treatment journey.